Mercer Global Advisors
TSHA icon

Mercer Global Advisors’s Taysha Gene Therapies TSHA Stock Holding History

Mercer Global Advisors’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.5K Buy
+1,539
New +$9.11K ﹤0.01% 5110

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Mercer Global Advisors's TSHA Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Taysha Gene Therapies (TSHA) in Q2 2026: 1,539 shares worth $10.5K. The stake represents ﹤0.01% of the portfolio and ranks #5110 among its holdings.

132 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Mercer Global Advisors held 1,539 shares of Taysha Gene Therapies worth $10.5K as of Q2 2026.
  • Taysha Gene Therapies was a new Mercer Global Advisors position in Q2 2026.
  • Taysha Gene Therapies made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #5110 holding.
  • 132 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.